top of page

Prevention of mother-to-child-transmission (PMCT)

Use of antiretrovirals is recommended for the prevention of mother-to-child transmission of HIV-1. The current WHO recommended regimen is as follows: where the pregnant woman does not yet need to start ART for therapeutic reasons, she should start Zidovudine (AZT) from 28 weeks or as soon as possible thereafter, be provided with single-dose Nevirapine (NVP) when entering labour, and be given AZT+3TC for one week following delivery. Meanwhile, whether the mother was on the above or standard ART, the child should be given single dose Nevirapine immediately after delivery and daily Zidovudine until one week old. Complementary measures that may also be used include caesarean section and formula feeding (7.2)

Fixed-Dose Combination

Fixed-dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Fixed drug. The most popular Fixed-Dose combinations are Stribild (elvitegravir + cobicistat + tenofovir + emtricitabine), by Gilead Sciences. Atripla (efavirenz + tenofovir + emtricitabine), by Gilead Sciences and Bristol-Myers Squibb. Complera (rilpivirine + tenofovir + emtricitabine), by Janssen Therapeutics and Gilead Sciences. (7.3)

Sperm Washing

Sperm washing is the process in which individual sperms are separated from the seminal fluid. The sperms are then used in intrauterine insemination (IUI) or in vitro fertilization (IVF). It can be used to decrease the risk of HIV transmission in HIV-positive fathers, because the HIV infection is carried by the seminal fluid rather than the sperm. (7.4)

Photo Citation (7.5), (7.6), (7.7)

Site Designed by LC Shorter / Ms. Keller / Christian Brothers Highschool 

bottom of page